Is there a role for periurethral collagen injection in the management of urodynamically proven mixed urinary incontinence?

Christina I. Poon, Philippe E. Zimmern

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives: To investigate the effectiveness of periurethral collagen injection (PCI) in patients presenting with symptoms of mixed urinary incontinence (MUI) and urodynamically demonstrated sphincter deficiency and detrusor overactivity. Methods: A retrospective review was performed on all patients undergoing PCI from February 1999 to February 2003, during which those with MUI were treated with PCI as first-line therapy. The inclusion criteria were MUI symptoms, detrusor overactivity on urodynamic study, stress urinary incontinence due to sphincter deficiency (determined from physical examination, stress test, urodynamic study with Valsalva leak point pressure, and cystography findings, without urethral hypermobility). The primary outcome measures were the Urogenital Distress Inventory (UDI), Incontinence Impact Questionnaire, and quality-of-life score and the need for anticholinergic medications or additional surgery. Comparisons were performed using the Wilcoxon signed ranks test and paired t test. Results: Of the 56 patients who underwent PCI, 43 presented with symptoms of MUI, and 16 of these (29%) had both detrusor overactivity and stress urinary incontinence on urodynamic study. The mean follow-up after PCI (without additional PCI) was 18 months (range 6 to 39). The mean age was 65 years (range 40 to 84). The mean Valsalva leak point pressure was 54 ± 40 cm H2O (range 18 to 146). Ten patients had undergone previous anti-incontinence procedures, and anticholinergic medications had failed in six. The questionnaire scores, indicating severe MUI/poor quality of life before PCI, improved after PCI: UDI question 1, 2.3 ± 0.8 versus 1.3 ± 1.0 (P = 0.021); UDI question 2, 2.1 ± 1.2 versus 1.4 ± 1.0 (P = 0.068); UDI question 3, 2.9 ± 0.4 versus 1.8 ± 1.2 (P = 0.010); and quality-of-life question, 8.6 ± 2.1 versus 5.2 ± 3.5 (P = 0.026). The mean injected volume/patient was 8.5 cm3 (range 5 to 17) within a mean of 1.9 treatments (range 1 to 3). Four patients continued taking anticholinergic medications and one proceeded to sling placement. Conclusions: The use of PCI as the primary/initial intervention in patients with MUI may be the preferred approach, particularly in patients with an elevated risk of anticholinergic medication side effects or when voiding dynamics preclude sling placement.

Original languageEnglish (US)
Pages (from-to)725-729
Number of pages5
JournalUrology
Volume67
Issue number4
DOIs
StatePublished - Apr 2006

Fingerprint

Urinary Incontinence
Collagen
Injections
Cholinergic Antagonists
Urodynamics
Equipment and Supplies
Stress Urinary Incontinence
Quality of Life
Pressure
Nonparametric Statistics
Exercise Test
Physical Examination
Outcome Assessment (Health Care)
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Is there a role for periurethral collagen injection in the management of urodynamically proven mixed urinary incontinence? / Poon, Christina I.; Zimmern, Philippe E.

In: Urology, Vol. 67, No. 4, 04.2006, p. 725-729.

Research output: Contribution to journalArticle

@article{5fffcf2b3c6449a389d1402bec2de873,
title = "Is there a role for periurethral collagen injection in the management of urodynamically proven mixed urinary incontinence?",
abstract = "Objectives: To investigate the effectiveness of periurethral collagen injection (PCI) in patients presenting with symptoms of mixed urinary incontinence (MUI) and urodynamically demonstrated sphincter deficiency and detrusor overactivity. Methods: A retrospective review was performed on all patients undergoing PCI from February 1999 to February 2003, during which those with MUI were treated with PCI as first-line therapy. The inclusion criteria were MUI symptoms, detrusor overactivity on urodynamic study, stress urinary incontinence due to sphincter deficiency (determined from physical examination, stress test, urodynamic study with Valsalva leak point pressure, and cystography findings, without urethral hypermobility). The primary outcome measures were the Urogenital Distress Inventory (UDI), Incontinence Impact Questionnaire, and quality-of-life score and the need for anticholinergic medications or additional surgery. Comparisons were performed using the Wilcoxon signed ranks test and paired t test. Results: Of the 56 patients who underwent PCI, 43 presented with symptoms of MUI, and 16 of these (29{\%}) had both detrusor overactivity and stress urinary incontinence on urodynamic study. The mean follow-up after PCI (without additional PCI) was 18 months (range 6 to 39). The mean age was 65 years (range 40 to 84). The mean Valsalva leak point pressure was 54 ± 40 cm H2O (range 18 to 146). Ten patients had undergone previous anti-incontinence procedures, and anticholinergic medications had failed in six. The questionnaire scores, indicating severe MUI/poor quality of life before PCI, improved after PCI: UDI question 1, 2.3 ± 0.8 versus 1.3 ± 1.0 (P = 0.021); UDI question 2, 2.1 ± 1.2 versus 1.4 ± 1.0 (P = 0.068); UDI question 3, 2.9 ± 0.4 versus 1.8 ± 1.2 (P = 0.010); and quality-of-life question, 8.6 ± 2.1 versus 5.2 ± 3.5 (P = 0.026). The mean injected volume/patient was 8.5 cm3 (range 5 to 17) within a mean of 1.9 treatments (range 1 to 3). Four patients continued taking anticholinergic medications and one proceeded to sling placement. Conclusions: The use of PCI as the primary/initial intervention in patients with MUI may be the preferred approach, particularly in patients with an elevated risk of anticholinergic medication side effects or when voiding dynamics preclude sling placement.",
author = "Poon, {Christina I.} and Zimmern, {Philippe E.}",
year = "2006",
month = "4",
doi = "10.1016/j.urology.2005.10.066",
language = "English (US)",
volume = "67",
pages = "725--729",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Is there a role for periurethral collagen injection in the management of urodynamically proven mixed urinary incontinence?

AU - Poon, Christina I.

AU - Zimmern, Philippe E.

PY - 2006/4

Y1 - 2006/4

N2 - Objectives: To investigate the effectiveness of periurethral collagen injection (PCI) in patients presenting with symptoms of mixed urinary incontinence (MUI) and urodynamically demonstrated sphincter deficiency and detrusor overactivity. Methods: A retrospective review was performed on all patients undergoing PCI from February 1999 to February 2003, during which those with MUI were treated with PCI as first-line therapy. The inclusion criteria were MUI symptoms, detrusor overactivity on urodynamic study, stress urinary incontinence due to sphincter deficiency (determined from physical examination, stress test, urodynamic study with Valsalva leak point pressure, and cystography findings, without urethral hypermobility). The primary outcome measures were the Urogenital Distress Inventory (UDI), Incontinence Impact Questionnaire, and quality-of-life score and the need for anticholinergic medications or additional surgery. Comparisons were performed using the Wilcoxon signed ranks test and paired t test. Results: Of the 56 patients who underwent PCI, 43 presented with symptoms of MUI, and 16 of these (29%) had both detrusor overactivity and stress urinary incontinence on urodynamic study. The mean follow-up after PCI (without additional PCI) was 18 months (range 6 to 39). The mean age was 65 years (range 40 to 84). The mean Valsalva leak point pressure was 54 ± 40 cm H2O (range 18 to 146). Ten patients had undergone previous anti-incontinence procedures, and anticholinergic medications had failed in six. The questionnaire scores, indicating severe MUI/poor quality of life before PCI, improved after PCI: UDI question 1, 2.3 ± 0.8 versus 1.3 ± 1.0 (P = 0.021); UDI question 2, 2.1 ± 1.2 versus 1.4 ± 1.0 (P = 0.068); UDI question 3, 2.9 ± 0.4 versus 1.8 ± 1.2 (P = 0.010); and quality-of-life question, 8.6 ± 2.1 versus 5.2 ± 3.5 (P = 0.026). The mean injected volume/patient was 8.5 cm3 (range 5 to 17) within a mean of 1.9 treatments (range 1 to 3). Four patients continued taking anticholinergic medications and one proceeded to sling placement. Conclusions: The use of PCI as the primary/initial intervention in patients with MUI may be the preferred approach, particularly in patients with an elevated risk of anticholinergic medication side effects or when voiding dynamics preclude sling placement.

AB - Objectives: To investigate the effectiveness of periurethral collagen injection (PCI) in patients presenting with symptoms of mixed urinary incontinence (MUI) and urodynamically demonstrated sphincter deficiency and detrusor overactivity. Methods: A retrospective review was performed on all patients undergoing PCI from February 1999 to February 2003, during which those with MUI were treated with PCI as first-line therapy. The inclusion criteria were MUI symptoms, detrusor overactivity on urodynamic study, stress urinary incontinence due to sphincter deficiency (determined from physical examination, stress test, urodynamic study with Valsalva leak point pressure, and cystography findings, without urethral hypermobility). The primary outcome measures were the Urogenital Distress Inventory (UDI), Incontinence Impact Questionnaire, and quality-of-life score and the need for anticholinergic medications or additional surgery. Comparisons were performed using the Wilcoxon signed ranks test and paired t test. Results: Of the 56 patients who underwent PCI, 43 presented with symptoms of MUI, and 16 of these (29%) had both detrusor overactivity and stress urinary incontinence on urodynamic study. The mean follow-up after PCI (without additional PCI) was 18 months (range 6 to 39). The mean age was 65 years (range 40 to 84). The mean Valsalva leak point pressure was 54 ± 40 cm H2O (range 18 to 146). Ten patients had undergone previous anti-incontinence procedures, and anticholinergic medications had failed in six. The questionnaire scores, indicating severe MUI/poor quality of life before PCI, improved after PCI: UDI question 1, 2.3 ± 0.8 versus 1.3 ± 1.0 (P = 0.021); UDI question 2, 2.1 ± 1.2 versus 1.4 ± 1.0 (P = 0.068); UDI question 3, 2.9 ± 0.4 versus 1.8 ± 1.2 (P = 0.010); and quality-of-life question, 8.6 ± 2.1 versus 5.2 ± 3.5 (P = 0.026). The mean injected volume/patient was 8.5 cm3 (range 5 to 17) within a mean of 1.9 treatments (range 1 to 3). Four patients continued taking anticholinergic medications and one proceeded to sling placement. Conclusions: The use of PCI as the primary/initial intervention in patients with MUI may be the preferred approach, particularly in patients with an elevated risk of anticholinergic medication side effects or when voiding dynamics preclude sling placement.

UR - http://www.scopus.com/inward/record.url?scp=33645970184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645970184&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2005.10.066

DO - 10.1016/j.urology.2005.10.066

M3 - Article

C2 - 16618559

AN - SCOPUS:33645970184

VL - 67

SP - 725

EP - 729

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4

ER -